The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Cytokines in breast cancer
Open accessAbstract
In recent decades many advances have occurred in the understanding of the role of cytokines in breast cancer. New signalling pathways of interleukin (IL)-1 family, IL-6, IL-11, IL-18, interferons (IFNs) and interferon regulatory factors 1 (IRF-1) and 2 (IRF-2) have been found within tumour microenvironments and in metastatic sites. Some cytokines (IL-1, IL-6, IL-11, TGFbeta) stimulate while others (IL-12, IL-18, IFNs) inhibit breast cancer proliferation and/or invasion. Similarly, high circulating levels of some cytokines seem to be favourable (soluble IL-2R) while others are unfavourable (IL-1beta, IL-6, IL-8, IL-10, IL-18, gp130) prognostic indicators. So far IL-2, IFNalpha, IFNbeta and occasionally IFNgamma, IL-6, IL-12 have been the cytokines used for anti tumour treatment of advanced breast cancer either to induce or increase hormone sensitivity and/or to stimulate cellular immunity. Disappointing results occurred in most trials; however, two long-term pilot studies suggest that IL-2 and IFNbeta, when used appropriately can have a positive effect on clinical benefit and overall survival of patients with minimal residual disease after chemotherapy or with disseminated disease controlled by conventional endocrine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and Molecular Immunology
Abbas, A. K., Lichtman, A. H., & Pillai, S. S. (1994) · Cited by 3,584
Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
Morgan, D. A., Ruscetti, F. W., & Gallo, R. (1976) · Science · doi:10.1126/science.181845 · Cited by 2,493
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Peptide Growth Factors and Their Receptors
Arai, K., Battey, J. F., Sporn, M. B., & Roberts, A. B. (1991) · Medical Entomology and Zoology · Cited by 1,225
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Thomson, A. W. (1994) · Cited by 1,116
Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., & Buzdar, A. U. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2197 · Cited by 738
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
The biology of IL-12: coordinating innate and adaptive immune responses
Watford, W. T., Moriguchi, M., Morinobu, A., & O’Shea, J. J. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00043-1 · Cited by 576
Trikha, M., Corringham, R. E., Klein, B., & Rossi, J. (2003) · PubMed · Cited by 506
Sidky, Y. A., & Borden, E. C. (1987) · PubMed · Cited by 494
Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer
Salgado, R., Junius, S., Benoy, I., Van Dam, P., Vermeulen, P., Van Marck, E., Huget, P., & Dirix, L. Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.10833 · Cited by 435
Benoy, I. H., Salgado, R., Van Dam, P., Geboers, K., Van Marck, E., Scharpé, S., Vermeulen, P. B., & Dirix, L. Y. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0812 · Cited by 356
Interferon-alpha in tumor immunity and immunotherapy
Belardelli, F., Ferrantini, M., Proietti, E., & Kirkwood, J. M. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00022-3 · Cited by 337
Bachelot, T., Ray-Coquard, I., Menetrier-Caux, C., Rastkha, M., Duc, A., & Blay, J.-Y. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600956 · Cited by 317
Zhang, G.-J., & Adachi, I. (1999) · PubMed · Cited by 306
Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies
ATZPODIEN, J. (1990) · The Lancet · doi:10.1016/0140-6736(90)93039-r · Cited by 292
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
Handbook of experimental pharmacology
Dix, C. J. (1984) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(84)90179-5 · Cited by 267
Purohit, A., Newman, S. P., & Reed, M. J. (2002) · Breast Cancer Research · doi:10.1186/bcr425 · Cited by 252
Kozłowski, L., Zakrzewska, I., Tokajuk, P., & Wojtukiewicz, M. Z. (2003) · PubMed · Cited by 248
Niwa, Y., Akamatsu, H., Niwa, H., Sumi, H., Ozaki, Y., & Abe, A. (2001) · PubMed · Cited by 245
Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.
Weber, J., Yang, J. C., Topalian, S. L., Parkinson, D. R., Schwartzentruber, D. S., Ettinghausen, S. E., Gunn, H., Mixon, A., Kim, H., & Cole, D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.499 · Cited by 216
Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer Patients
Benoy, I., Salgado, R., Colpaert, C., Weytjens, R., Vermeulen, P. B., & Dirix, L. Y. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.n.008 · Cited by 188
Li, M., Zhou, J., Sasano, H., Suzuki, T., Zeitoun, K. M., & Bulun, S. E. (2001) · PubMed · Cited by 169
Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL
Clarke, N., Jimenez-Lara, A. M., Voltz, E., & Gronemeyer, H. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600302 · Cited by 163
Pantschenko, A., Pushkar, I., Anderson, K., Wang, Y., Miller, L., Kurtzman, S., Barrows, G., & Kreutzer, D. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.2.269 · Cited by 162
Bouker, K. B., Skaar, T. C., Riggins, R. B., Harburger, D. S., Fernández, D., Zwart, A. L., Wang, A., & Clarke, R. C. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi113 · Cited by 159
Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele, A. M., Martin, A.-M., Mick, R., Gor, P. P., Wray, L., Klein-Cabral, M., Athanasiadis, G., Colligan, T., Stadtmauer, E. A., & Weber, B. (2003) · PubMed · Cited by 155
Wigginton, J. M., Gruys, E., Geiselhart, L., Subleski, J. J., Komschlies, K. L., Park, J., Wiltrout, T. A., Nagashima, K., Back, T. C., & Wiltrout, R. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10128 · Cited by 136
Stewart, A. K., Lassam, N. J., Quirt, I. C., Bailey, D. J., ROTSTEIN, L. E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300833 · Cited by 127
Parihar, R., Nadella, P. C., Lewis, A., Jensen, R. R., Hoff, C. D., Dierksheide, J. E., VanBuskirk, A. M., MAGRO, C. M. J., Young, D. C., Shapiro, C. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0265 · Cited by 121
Kim, P., Armstrong, M., Liu, Y., Yan, P., Bucher, B. T., Zuckerbraun, B., Gambotto, A., Billiar, T., & Yim, J. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207023 · Cited by 115
Lissoni, P., Barni, S., Tancini, G., Ardizzoia, A., Ricci, G., Aldeghi, R., Brivio, F., Tisi, E., Rovelli, F., Rescaldani, R., et al. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.34 · Cited by 110
Donovan, J. C. H., & Slingerland, J. M. (2000) · Breast Cancer Research · doi:10.1186/bcr43 · Cited by 107
Bozcuk, H. S., Uslu, G., Samur, M., Yıldız, M., Özben, T., Özdoğan, M., Artaç, M., Altunbaş, H., Akan, I., & Savaş, B. (2004) · Cytokine · doi:10.1016/j.cyto.2004.04.002 · Cited by 106
Lymphokines and the immune response: the central role of interleukin-2
Swain, S. L. (1991) · Current Opinion in Immunology · doi:10.1016/0952-7915(91)90028-y · Cited by 96
Kang, J. X., Liu, J., Wang, J., He, C., & Li, F. P. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi154 · Cited by 96
Selander, K. S., Li, L., Watson, L., Merrell, M. A., Dahmen, H., Heinrich, P. C., Müller‐Newen, G., & Harris, K. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2516 · Cited by 92
Einav, U., Tabach, Y., Getz, G. A., Yitzhaky, A., Özbek, U., Amariglio, N., Izraeli, S., Rechavi, G., & Domany, E. (2005) · Oncogene · doi:10.1038/sj.onc.1208797 · Cited by 91
Interleukin-1 Family Expression in Human Breast Cancer: Interleukin-1 Receptor Antagonist
MILLER, L. J., Kurtzman, S. H., Anderson, K. L., Wang, Y., Stankus, M., Renna, M., Lindquist, R. R., Barrows, G. H., & Kreutzer, D. L. (2000) · Cancer Investigation · doi:10.3109/07357900009012171 · Cited by 85
Honma, S., Shimodaira, K., Shimizu, Y., Tsuchiya, N., Saito, H., Yanaihara, T., & Okai, T. (2002) · Endocrine Journal · doi:10.1507/endocrj.49.371 · Cited by 79
Morgan, H., Tumber, A., & Hill, P. A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20056 · Cited by 77
Xue, L., Firestone, G. L., & Bjeldanes, L. F. (2005) · Oncogene · doi:10.1038/sj.onc.1208434 · Cited by 76
Interferon Regulatory Factor Expression in Human Breast Cancer
Doherty, G. M., Boucher, L. D., Sorenson, K., & Lowney, J. K. (2001) · Annals of Surgery · doi:10.1097/00000658-200105000-00005 · Cited by 71
Cui, X.-F., Imaizumi, T., Yoshida, H., Borden, E. C., & Satoh, K. (2004) · Biochemistry and Cell Biology · doi:10.1139/o04-041 · Cited by 71
Bouker, K. B., Skaar, T. C., Fernández, D., O’Brien, K. A., Riggins, R. B., Cao, D., & Clarke, R. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3602 · Cited by 70
Iacopetta, B. M., Grieu, F., & Joseph, D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601545 · Cited by 67
Singer, C. F., Kronsteiner, N., Hudelist, G., Márton, E., Walter, I., Kubista, M., Czerwenka, K. F., Schreiber, M., Seifert, M., & Kubista, E. (2003) · PubMed · Cited by 66
Interferon Regulatory Factor 1 (IRF-1) and IRF-2 Expression in Breast Cancer Tissue Microarrays
Connett, J. M., Badri, L., Giordano, T. J., Connett, W. C., & Doherty, G. M. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.587 · Cited by 56
Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications
Kurebayashi, J. (2000) · Breast Cancer · doi:10.1007/bf02967443 · Cited by 56
Merendino, R. A., Gangemi, S., Ruello, A., Bene, A., Losi, E., Lonbardo, G., & Purello-D'Ambrosio, F. (2001) · The International Journal of Biological Markers · doi:10.1177/172460080101600207 · Cited by 52
Günel, N., Çoşkun, U., Sancak, B., Hasdemır, O., Şare, M., Bayram, O., Çelenkoğlu, G., & Ozkan, S. (2003) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000027416.15170.53 · Cited by 41
Bezwoda, W. R., & Meyer, K. L. (1990) · PubMed · Cited by 40
CYP2C and IL-6 expression in breast cancer
Knüpfer, H., Schmidt, R., Stanitz, D., et al. (2003) · The Breast · doi:10.1016/j.breast.2003.07.002 · Cited by 35
Chatterji, U. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh121 · Cited by 35
CHANGES IN CYTOKINE PRODUCTION OF BREAST CANCER PATIENTS TREATED WITH INTERFERONS
Barak, V., Kalickman, I., Nisman, B., Farbstein, H., Fridlender, Z. G., Baider, L., Kaplan, A., Stephanos, S., & Peretz, T. (1998) · Cytokine · doi:10.1006/cyto.1998.0378 · Cited by 34
Kovacs, E. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00079-8 · Cited by 33
Nishimura, R., 長尾, 和., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., Yamashita, H., Fukuda, M., Mizumoto, T., & Hamamoto, R. (2000) · Oncology · doi:10.1159/000012155 · Cited by 33
Cytokine Genotype Polymorphisms in Breast Carcinoma: Associations of TGF-β1 with Relapse
Skerrett, D., Moore, E. M., Bernstein, D. S., & Vahdat, L. T. (2005) · Cancer Investigation · doi:10.1081/cnv-200055954 · Cited by 33
Seymour, L., & Bezwoda, W. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.339 · Cited by 32
Toma, S., Raffo, P., Nicolò, G., Canavese, G., Margallo, E., Vecchio, C., Dastoli, G., Iacona, I., & Regazzi-Bonora, M. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.5.991 · Cited by 32
The interferon-β and tamoxifen combination induces apoptosis using thioredoxin reductase
Lindner, D. J., Hofmann, E. R., Karra, S., & Kalvakolanu, D. V. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(00)00021-5 · Cited by 29
Saha, A., Dhir, A., Ranjan, A., Gupta, V., Bairwa, N. K., & Bamezai, R. N. K. (2005) · Immunogenetics · doi:10.1007/s00251-005-0783-5 · Cited by 28
Buzzi, F., Brugia, M., Rossi, G., Giustini, L., Scoponi, C., & Sica, G. (1992) · PubMed · Cited by 27
Self-citationSabbioni, M. E. E., Siegrist, H. P., Bacchi, M., Bernhard, J., Castiglione, M. M., Thurlimann, B. J. K., Bonnefoi, H. R., Perey, L., Herrmann, R., Goldhirsch, A., et al. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006379925343 · Cited by 26
Liu, L., & Gudas, L. J. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10173 · Cited by 25
Tamoxifen and interferon-beta for the treatment of metastatic breast cancer
Repetto, L., Giannessi, P. G., Campora, E., et al. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01806190 · Cited by 22
Steroid receptor enhancement by natural interferon-β in advanced breast cancer
Sica, G., Iacopino, F., Lama, G., Amadori, D., Baroni, M., Sardo, F. L., Malacarne, P., Marchetti, P., Pellegrini, A., Zaniboni, A., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90378-s · Cited by 17
Banks, R. E., Forbes, M. A., Patel, P. M., et al. (2000) · Cytokine · doi:10.1006/cyto.1999.0556 · Cited by 15
Beta-interferon, retinoids and tamoxifen combination in advanced breast cancer.
Recchia, F., Rea, S., Filippis, S. D., Rosselli, M., Corrao, G., Gulino, A., & Sica, G. (1998) · PubMed · Cited by 9
Natural interferon-beta and tamoxifen in hormone-resistant patients with advanced breast cancer.
Buzzi, E., Brugia, M., Trippa, F., Rossi, G., Trivisonne, R., Giustini, L., Pinaglia, D., Capparella, V., & Sica, G. (1995) · PubMed · Cited by 9
Self-citationTamoxifen and Alpha Interferon in Advanced Breast Cancer
Miglietta, L., Repetto, L., Gardin, G., AMOROSO, D., Giudici, S., Naso, C., Merlini, L., Queirolo, P., Campora, E., Pronzato, P., et al. (1991) · Journal of Chemotherapy · doi:10.1080/1120009x.1991.11739125 · Cited by 9
Martin, J., & Symonds, A. L. J. (2002) · Oncology Reports · doi:10.3892/or.9.2.379 · Cited by 8
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Cited by
Picon‐Ruiz, M., Morata‐Tarifa, C., Valle‐Goffin, J. J., Friedman, E. R., & Slingerland, J. M. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21405 · Cited by 893
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
The Role of Cytokines in Breast Cancer Development and Progression
Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I., & Morales-Montor, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0026 · Cited by 490
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Tumor exosomes inhibit differentiation of bone marrow dendritic cells
Yu, S., Liu, C., Su, K., Wang, J., Liu, Y., Zhang, L., Li, C., Cong, Y., Kimberly, R., Grizzle, W. E., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6867 · Cited by 425
Metadata
- Authors
- Nicolini, A., Carpi, A., & Rossi, G.
- Venue
- Cytokine & Growth Factor Reviews
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 17
- Issue
- 5
- Pages
- 325-337
- ISSN
- 1359-6101 (ISSN-L)
- OpenAlex
- W2082634661
- Cited by
- 279
- References
- 75
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.